Antihistamines, Amantadine and Evolution of COVID-19
Evaluation of Treatments With Antihistamines and Amantadine in the Evolution of the SARS-CoV-2 Infection
Consorci Sanitari de Terrassa
140,660 participants
Mar 1, 2020
OBSERVATIONAL
Conditions
Summary
The rates of symptomatic COVID19 infection, hospital admission among COVID19 cases and survival would be quantified in patiens chronically treated with antihistamines or amantadine, with the aim of determining the role of antihistamines and amantadine in the evolution of COVID19.
Eligibility
Exclusion Criteria1
- \-
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Observation of the rate of COVID19 infection, the rate of hospitalization, the rate of survival and postcovid syndrome and thrombosis among patients previously treated with antihistamines
Observation of the rate of COVID19 infection, the rate of hospitalization, the rate of survival and the rate of postcovid syndrome and thrombosis among patients previously treated with amantadine
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05504057